Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | EML4 - ALK |
| Therapy | Alectinib + Carboplatin + Irinotecan |
| Indication/Tumor Type | lung small cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| EML4 - ALK | lung small cell carcinoma | predicted - sensitive | Alectinib + Carboplatin + Irinotecan | Case Reports/Case Series | Actionable | In a clinical case study, treatment with the combination of Paraplatin (carboplatin), Camptosar (irinotecan), and Alecensa (alectinib) resulted in a partial response with decrease in the hilar mass and mediastinal lymph nodes in a patient with metastatic small cell lung cancer harboring EML4-ALK (PMID: 40106998). | 40106998 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (40106998) | ALK-EML4 Fusion in Small Cell Lung Cancer: Clinical and Molecular Insights From a Rare Case. | Full reference... |